Previous 10 | Next 10 |
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023 PR Newswire CRANFORD, N.J. , Sept. 18, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage bi...
Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir PR Newswire CRANFORD, N.J. , Sept. 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) mourns the loss of longtime board member, Howard Safir , w...
2023-09-08 09:05:46 ET More on Citius Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius Pharmaceuticals Financial information for Citius Pharmaceuticals Citius gains as pivotal trial for antibiotic hits key mile...
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™ PR Newswire Resubmission to FDA planned for early 2024 CRANFORD, N.J. , Sept. 8, 2023 ...
Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023 PR Newswire CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopha...
2023-08-14 17:11:15 ET Citius Pharmaceuticals press release ( NASDAQ: CTXR ): Q3 GAAP EPS of -$0.06 beats by $0.01 . Cash and cash equivalents of $33.3 million as of June 30, 2023. For further details see: Citius Pharmaceuticals GAAP EPS of -$0.06 beats by $0.01
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update PR Newswire $33.3 million in cash and cash equivalents as of June 30, 2023 ; runway through August 2024 CRANFORD, N.J. , Aug. 14, 2023 ...
2023-08-10 09:39:18 ET More on Citius Pharmaceuticals Citius Pharmaceuticals: Steer Clear From This One Citius gains on positive mid-stage data for hemorrhoids therapy Citius extends gains on advancing efforts to spin off oncology asset Citius Pharmaceuticals...
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial PR Newswire CRANFORD, N.J. , Aug. 10, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated ...
2023-07-31 08:19:22 ET Checkpoint Therapeutics ( CKPT ) -14% announces $10 Million registered direct offering priced at-the-market. Citius Pharmaceuticals ( CTXR ) -13% . BioNexus Gene Lab Corp. ( BGLC ) -13% . Blue Star Foods Corp. ( BSFC ) -...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...